| Hepatocellular carcinoma in the era of immunotherapy HW Sim, J Knox Current Problems in Cancer 42 (1), 40-48, 2018 | 186 | 2018 |
| First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium JM Ruiz-Morales, M Swierkowski, JC Wells, AP Fraccon, F Pasini, ... European Journal of Cancer 65, 102-108, 2016 | 86 | 2016 |
| Randomized phase III study of FOLFOX alone or with pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (SEQUOIA) JR Hecht, S Lonardi, J Bendell, HW Sim, T Macarulla, CD Lopez, ... Journal of Clinical Oncology 39 (10), 1108-1118, 2021 | 69 | 2021 |
| Checkpoint inhibitors in patients with metastatic renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium SM Yip, C Wells, R Moreira, A Wong, S Srinivas, B Beuselinck, C Porta, ... Cancer 124 (18), 3677-3683, 2018 | 64 | 2018 |
| A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study HW Sim, KL McDonald, Z Lwin, EH Barnes, M Rosenthal, MC Foote, ... Neuro-oncology 23 (10), 1736-1749, 2021 | 56 | 2021 |
| A comprehensive proteomic SWATH-MS workflow for profiling blood extracellular vesicles: a new avenue for glioma tumour surveillance S Hallal, A Azimi, H Wei, N Ho, MYT Lee, HW Sim, J Sy, B Shivalingam, ... International journal of molecular sciences 21 (13), 4754, 2020 | 46 | 2020 |
| Contemporary management of high-grade gliomas HW Sim, ER Morgan, WP Mason CNS oncology 7 (01), 51-65, 2018 | 42 | 2018 |
| First-line sunitinib or pazopanib in metastatic renal cell carcinoma: the Canadian experience AKA Lalani, H Li, DYC Heng, L Wood, A Kalirai, GA Bjarnason, HW Sim, ... Canadian Urological Association Journal 11 (3-4), 112, 2017 | 40 | 2017 |
| Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results From the International Metastatic Renal Cell Carcinoma Database … F Donskov, W Xie, A Overby, JC Wells, AP Fraccon, CS Sacco, C Porta, ... European urology oncology 3 (4), 530-539, 2020 | 39 | 2020 |
| Deep sequencing of small RNAs from neurosurgical extracellular vesicles substantiates miR-486-3p as a circulating biomarker that distinguishes glioblastoma from lower-grade … S Hallal, S Ebrahim Khani, H Wei, MYT Lee, HW Sim, J Sy, B Shivalingam, ... International journal of molecular sciences 21 (14), 4954, 2020 | 33 | 2020 |
| PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities HW Sim, E Galanis, M Khasraw Cancers 14 (4), 1003, 2022 | 31 | 2022 |
| Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma J Lewin, S Garg, BY Lau, BC Dickson, F Traub, N Gokgoz, AM Griffin, ... International Journal of Cancer 142 (1), 57-65, 2018 | 29 | 2018 |
| Case report: a case of pituitary carcinoma treated with sequential dual immunotherapy and vascular endothelial growth factor inhibition therapy LS Lamb, HW Sim, AI McCormack Frontiers in Endocrinology 11, 576027, 2020 | 28 | 2020 |
| Exploring the role of novel medical therapies for aggressive pituitary tumors: a review of the literature—“are we there yet?” LS Lamb, HW Sim, AI McCormack Cancers 12 (2), 308, 2020 | 27 | 2020 |
| Prognosis of patients with hepatocellular carcinoma treated with sorafenib: a comparison of five models in a large Canadian database HH Samawi, HW Sim, KK Chan, MA Alghamdi, RM Lee‐Ying, JJ Knox, ... Cancer Medicine 7 (7), 2816-2825, 2018 | 25 | 2018 |
| Measuring the impact of an adolescent and young adult program on addressing patient care needs L Mitchell, S Tam, J Lewin, A Srikanthan, C Heck, D Hodgson, ... Journal of Adolescent and Young Adult Oncology 7 (5), 612-617, 2018 | 22 | 2018 |
| Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas HW Sim, R Nejad, W Zhang, F Nassiri, W Mason, KD Aldape, G Zadeh, ... Clinical Cancer Research 25 (11), 3366-3373, 2019 | 20 | 2019 |
| Randomized Phase III Study of FOLFOX Alone and with Pegilodecakin as Second-line Therapy in Patients with Metastatic Pancreatic Cancer (SEQUOIA). JR Hecht, S Lonardi, JC Bendell, HW Sim, T Macarulla, CD Lopez, ... Journal of Clinical Oncology 38 (4_suppl), 637-637, 2020 | 19 | 2020 |
| Second‐line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real‐world eligibility for cabozantinib … AS Fung, VC Tam, DE Meyers, HW Sim, JJ Knox, V Zaborska, J Davies, ... Cancer Medicine 9 (13), 4640-4647, 2020 | 18 | 2020 |
| Brain metastases in breast cancer HW Sim, PG Morris, S Patil, M Khasraw Expert review of anticancer therapy 14 (2), 173-183, 2014 | 16 | 2014 |
